CLOs on the Move

Patient Care Technology Systems

www.pcts.com

 
Patient Care Technology Systems is a Mission Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pcts.com

  • Mission Viejo, CA USA 92691
  • Phone: 704.341.5797

Executives

Name Title Contact Details

Similar Companies

Audiometrics

Audiometrics is a Oceanside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Interim Healthcare of Greenville

Interim Healthcare of Greenville is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rayant

Rayant is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dignified Assisted Living

Dignified Assisted Living is a Rogers, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic